TIDMOBD
Oxford BioDynamics PLC
18 September 2018
18 September 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Consortium including Oxford BioDynamics receives EUR4 million
Horizon 2020 award
-- Horizon 2020 is the largest European funding programme for research and innovation
-- The consortium brings together established leaders in
theoretical and experimental epigenetic research to advance the use
of predictive epigenetics into real world applications
-- OBD, as an industry partner, is well positioned to access
commercial opportunities arising from successful new applications
of the EpiSwitch(TM) technology
Oxford BioDynamics Plc is pleased to announce that it has been
chosen as an industrial partner in a Horizon 2020 international
research and innovation collaboration. The initiative on
"Predictive Epigenetics" (PEP-NET), which has been granted EUR4
million, brings together an international consortium of 11 leading
epigenetic research centres and five partner organisations* to
develop practical translation of epigenetic regulation into
therapeutically actionable outcomes.
The PEP-NET consortium comprises experimentalists and
theoreticians whose goal is to develop a joint predictive modelling
framework to further the understanding of fundamental epigenetic
mechanisms. The outcome will present real world applications for
the development of new technologies, and diagnostic and therapeutic
tools to benefit patients.
This will be an important opportunity for OBD to increase
utilisation of its EpiSwitch(TM) platform and further develop its
technology globally, while helping to improve understanding of
epigenetic controls and mechanisms. As an industry partner in this
initiative, all parties will have access to OBD's intellectual
property for research purposes only.
Consortium member Professor Leonie Ringrose, Institute of
Biology, Humboldt University, Berlin, commented:
"Epigenetic mechanisms are profoundly implicated in human health
and disease. Despite the availability of large amounts of molecular
data sets today, the field is still far from a satisfactory
mechanistic understanding of many epigenetic processes. This unique
collaboration of frontline researchers and commercial companies
aims to combine quantitative experiments, predictive theoretical
models, new modeling of data analysis and latest industrial tools
of detection and monitoring to understand epigenetic regulation,
with the aim to achieve both deeper fundamental understanding and
better practical translation of epigenetic regulation into
actionable patient stratifications. We have seen the practical
value of EpiSwitch(TM) and believe this powerful platform will
allow us to develop real world solutions.
PEP-NET will train a generation of European researchers to
combine quantitative experiments with predictive theoretical
models, and will exploit this knowledge to answer both basic and
applied questions in epigenetics."
Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, added:
"We are delighted to join such a powerful and creative group of
established leaders in epigenetic research. Our technology will
help better the understanding of epigenetic controls and
mechanisms, with the ultimate goal to help translate latest
epigenetic insights for the benefit of novel successful therapies,
as well as patient diagnosis and prognosis. We strongly believe
that our platform could be creatively utilised in many new ways to
contribute to the frontline research and to further the development
of OBD's EpiSwitch(TM) technology globally. We are well aware how
much the industry is looking for robust biomarkers with predictive
and prognostic disseminating power. This is very much a question of
understanding epigenetic controls, if we are to deliver reliable
practical tools for applications in personalised medicine. "
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
About Horizon 2020
Horizon 2020 is the biggest EU Research and Innovation programme
ever with nearly EUR80 billion of funding available over 7 years
(2014 to 2020) - in addition to the private investment that this
money will attract. It promises more breakthroughs, discoveries and
world-firsts by taking great ideas from the lab to the market.
For further information, please see:
https://ec.europa.eu/programmes/horizon2020/en
*About the PEP-NET Consortium
The PEP-NET consortium is led by Professor Leonie Ringrose at
the Institute of Biology, Humboldt University (Berlin). It will
also involve Max-Planck from the Institute for Molecular Genetics
(Munich), and Computational and System Biology at John Innes Centre
(Norwich), Niels Bohr at the Institute at University of Copenhagen,
Friedrich Miescher at the Institute for Biomedical Research
(Basel), European Research Centre for Biology and Medicine
(Strasbourg), the Institute for Medical Systems biology at Max
Delbruck Centre for Molecular Medicine (Berlin-Buch), the
Department of Biochemistry at the University of Oxford, the
Department of Physics at the University of Naples, the Centre of
Experimental Imaging at the Hospital of St Raphael (Milan), as well
as Diagenode (Belgium). Other partner organisations include the
School of Biological Sciences at the University of Adelaide, the
Department of Physiology at the University of Pennsylvania, Oxford
Nanoimaging Ltd, and the University of East Anglia.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGURCBUPRGCM
(END) Dow Jones Newswires
September 18, 2018 02:02 ET (06:02 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024